Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)

  • Committee for the Korean Guidelines for the Management of Dyslipidemia (Committee for the Korean Guidelines for the Management of Dyslipidemia)
  • Received : 2016.02.11
  • Accepted : 2016.04.12
  • Published : 2016.05.30
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Ministry of Health and Welfare, Korea Centers for Disease Control and Prevention. Korea Health Statistics 2012: Korea National Health and Nutrition Examination Survey (KNHANES V-3). Cheongwon: Korea Centers for Disease Control and Prevention; 2013.
  2. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014;129:e28-e292. https://doi.org/10.1161/01.cir.0000441139.02102.80
  3. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818. https://doi.org/10.1093/eurheartj/ehr158
  4. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1-45. https://doi.org/10.1161/01.cir.0000437738.63853.7a
  5. Jee SH, Jang Y, Oh DJ, et al. A coronary heart disease prediction model: the Korean Heart Study. BMJ Open 2014;4:e005025. https://doi.org/10.1136/bmjopen-2014-005025
  6. World Health Organization (CH). Global Health Observatory (GHO) data. Deaths from NCDs [Internet]. Geneva: World Health Organization; 2012 [cited 2015 May 19]. Available from: http://www.who.int/gho/ncd/mortality_morbidity/ncd_total/en/index.html.
  7. Kim RB, Kim BG, Kim YM, et al. Trends in the incidence of hospitalized acute myocardial infarction and stroke in Korea, 2006-2010. J Korean Med Sci 2013;28:16-24. https://doi.org/10.3346/jkms.2013.28.1.16
  8. Kim HC, Oh SM. Noncommunicable diseases: current status of major modifiable risk factors in Korea. J Prev Med Public Health 2013;46:165-72. https://doi.org/10.3961/jpmph.2013.46.4.165
  9. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. https://doi.org/10.1161/01.CIR.0000133317.49796.0E
  10. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S49-73. https://doi.org/10.1161/01.cir.0000437741.48606.98
  11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
  12. Jun KR, Park HI, Chun S, Park H, Min WK. Effects of total cholesterol and triglyceride on the percentage difference between the low-density lipoprotein cholesterol concentration measured directly and calculated using the Friedewald formula. Clin Chem Lab Med 2008;46:371-5.
  13. Miller WG, Myers GL, Sakurabayashi I, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem 2010;56:977-86. https://doi.org/10.1373/clinchem.2009.142810
  14. Bachorik PS, Ross JW; The National Cholesterol Education Program Working Group on Lipoprotein Measurement. National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. Clin Chem 1995;41:1414-20.
  15. Arai H, Sasaki J, Teramoto T. Comment on the new guidelines in USA by the JAS guidelines committee. J Atheroscler Thromb 2014;21:79-81. https://doi.org/10.5551/jat.ED001
  16. Vaucher J, Marques-Vidal P, Preisig M, Waeber G, Vollenweider P. Population and economic impact of the 2013 ACC/AHA guidelines compared with European guidelines to prevent cardiovascular disease. Eur Heart J 2014;35:958-9. https://doi.org/10.1093/eurheartj/ehu064
  17. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35. https://doi.org/10.1056/NEJMoa050461
  18. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59. https://doi.org/10.1056/NEJMoa061894
  19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22. https://doi.org/10.1016/S0140-6736(02)09327-3
  20. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16. https://doi.org/10.1001/jama.292.11.1307
  21. Lee KH, Jeong MH, Kim HM, et al. Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol. J Am Coll Cardiol 2011;58:1664-71. https://doi.org/10.1016/j.jacc.2011.05.057
  22. Norris JW, Zhu CZ, Bornstein NM, Chambers BR. Vascular risks of asymptomatic carotid stenosis. Stroke 1991;22:1485-90. https://doi.org/10.1161/01.STR.22.12.1485
  23. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994;90:1679-87. https://doi.org/10.1161/01.CIR.90.4.1679
  24. Hertzer NR. Fatal myocardial infarction following abdominal aortic aneurysm resection. Three hundred forty-three patients followed 6--11 years postoperatively. Ann Surg 1980;192:667-73. https://doi.org/10.1097/00000658-198019250-00013
  25. Sukhija R, Aronow WS, Sandhu R, Kakar P, Babu S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 2006;97:279-80. https://doi.org/10.1016/j.amjcard.2005.08.033
  26. Schouten O, Boersma E, Hoeks SE, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med 2009;361:980-9. https://doi.org/10.1056/NEJMoa0808207
  27. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 2004;39:967-75. https://doi.org/10.1016/j.jvs.2004.01.004
  28. Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102:1014-9. https://doi.org/10.1161/01.CIR.102.9.1014
  29. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987;59:750-5. https://doi.org/10.1016/0002-9149(87)91086-1
  30. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-owering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25. https://doi.org/10.1016/S0140-6736(08)60104-X
  31. Jonas MA, Oates JA, Ockene JK, Hennekens CH; American Heart Association. Statement on smoking and cardiovascular disease for health care professionals. Circulation 1992;86:1664-9. https://doi.org/10.1161/01.CIR.86.5.1664
  32. Selmer R. Blood pressure and twenty-year mortality in the city of Bergen, Norway. Am J Epidemiol 1992;136:428-40. https://doi.org/10.1093/oxfordjournals.aje.a116516
  33. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15. https://doi.org/10.1161/01.CIR.79.1.8
  34. Rissanen AM, Nikkila EA. Coronary artery disease and its risk factors in families of young men with angina pectoris and in controls. Br Heart J 1977;39:875-83. https://doi.org/10.1136/hrt.39.8.875
  35. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47. https://doi.org/10.1161/01.CIR.97.18.1837
  36. Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am 1990;19:783-91.
  37. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005;165:725-30. https://doi.org/10.1001/archinte.165.7.725
  38. Poobalan A, Aucott L, Smith WC, et al. Effects of weight loss in overweight/obese individuals and long-term lipid outcomes--a systematic review. Obes Rev 2004;5:43-50. https://doi.org/10.1111/j.1467-789X.2004.00127.x
  39. Rees K, Dyakova M, Wilson N, Ward K, Thorogood M, Brunner E. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev 2013;12:CD002128.
  40. Ministry of Health and Welfare, Korea Centers for Disease Control and Prevention. Korea Health Statistics 2011: Korea National Health and Nutrition Examination Survey (KNHANES V-2). Cheongwon; Korea Centers for Disease Control and Prevention; 2012.
  41. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003;77:1146-55. https://doi.org/10.1093/ajcn/77.5.1146
  42. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997;65(5 Suppl):1645S-54. https://doi.org/10.1093/ajcn/65.5.1645S
  43. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999;69:30-42. https://doi.org/10.1093/ajcn/69.1.30
  44. Chrysohoou C, Panagiotakos DB, Pitsavos C, et al. Effects of chronic alcohol consumption on lipid levels, inflammatory and haemostatic factors in the general population: the 'ATTICA' Study. Eur J Cardiovasc Prev Rehabil 2003;10:355-61. https://doi.org/10.1097/01.hjr.0000065928.57001.4d
  45. Hong S, Song Y, Lee KH, et al. A fruit and dairy dietary pattern is associated with a reduced risk of metabolic syndrome. Metabolism 2012;61:883-90. https://doi.org/10.1016/j.metabol.2011.10.018
  46. Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation 2013;128:873-934. https://doi.org/10.1161/CIR.0b013e31829b5b44
  47. Taylor RS, Brown A, Ebrahim S, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004;116:682-92. https://doi.org/10.1016/j.amjmed.2004.01.009
  48. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002;347:1483-92. https://doi.org/10.1056/NEJMoa020194
  49. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 2007;116:1081-93. https://doi.org/10.1161/CIRCULATIONAHA.107.185649
  50. Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: another look at a meta-analysis using prediction intervals. Prev Med 2009;49:473-5. https://doi.org/10.1016/j.ypmed.2009.09.018
  51. Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Prev Med 2009;48:9-19. https://doi.org/10.1016/j.ypmed.2008.10.010
  52. Blair SN, Haskell WL. Objectively measured physical activity and mortality in older adults. JAMA 2006;296:216-8. https://doi.org/10.1001/jama.296.2.216
  53. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701. https://doi.org/10.1093/eurheartj/ehs092
  54. Ewald N, Hardt PD, Kloer HU. Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol 2009;20:497-504. https://doi.org/10.1097/MOL.0b013e3283319a1d
  55. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61. https://doi.org/10.1016/S0140-6736(05)67667-2
  56. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010;210:353-61. https://doi.org/10.1016/j.atherosclerosis.2009.12.023
  57. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006;189:19-30. https://doi.org/10.1016/j.atherosclerosis.2006.02.012
  58. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90. https://doi.org/10.1016/S0140-6736(12)60367-5
  59. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2003;2:517-26. https://doi.org/10.1038/nrd1112
  60. Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation 2004;110:886-92. https://doi.org/10.1161/01.CIR.0000139312.10076.BA
  61. Gotto AM Jr, Opie LH. Lipid-modifying and antiatherosclerotic drugs. In: Opie LH, Gersh BJ, editors. Drugs for the heart. 8th ed. Philadelphia (PA): Elsevier Saunders; 2013. p.398-435.
  62. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-60.
  63. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010;105:69-76. https://doi.org/10.1016/j.amjcard.2009.08.651
  64. Kwon JE, Kim Y, Hyun S, et al. Cholesterol lowering effects of low-dose statins in Korean patients. J Lipid Atheroscler 2014;3:21-8. https://doi.org/10.12997/jla.2014.3.1.21
  65. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368:1155-63. https://doi.org/10.1016/S0140-6736(06)69472-5
  66. Shepherd J, Blauw GJ, Murphy MB, et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30. https://doi.org/10.1016/S0140-6736(02)11600-X
  67. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-9. https://doi.org/10.1016/S0140-6736(08)61240-4
  68. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92. https://doi.org/10.1016/S0140-6736(11)60739-3
  69. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009;360:1395-407. https://doi.org/10.1056/NEJMoa0810177
  70. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42. https://doi.org/10.1016/S0140-6736(09)61965-6
  71. U.S. Food and Drug Administration. FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. Rockville (MD): U.S. Food and Drug Administration; 2012.
  72. Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010;74:956-64. https://doi.org/10.1212/WNL.0b013e3181d6476a
  73. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002;18:269-76. https://doi.org/10.1185/030079902125000516
  74. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:2969-89. https://doi.org/10.1210/jc.2011-3213
  75. Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D. Fibrate-nduced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000;15:1993-9. https://doi.org/10.1093/ndt/15.12.1993
  76. Grundy SM, Mok HY, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981;22:24-36.
  77. Cannon CP; the IMPROVE IT Investigators. IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Circulation 2014;130:2109.
  78. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002;112:298-304. https://doi.org/10.1016/S0002-9343(01)01114-7
  79. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308:1024-33. https://doi.org/10.1001/2012.jama.11374
  80. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009;8:453-63. https://doi.org/10.1016/S1474-4422(09)70058-4
  81. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160-236. https://doi.org/10.1161/STR.0000000000000024
  82. Hyre AD, Fox CS, Astor BC, Cohen AJ, Muntner P. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am J Kidney Dis 2007;49:37-45. https://doi.org/10.1053/j.ajkd.2006.09.017
  83. Tonelli M, Keech A, Shepherd J, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 2005;16:3748-54. https://doi.org/10.1681/ASN.2005070779
  84. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-owering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16. https://doi.org/10.1016/S0140-6736(03)13636-7
  85. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010;160:785-94.e10. https://doi.org/10.1016/j.ahj.2010.08.012
  86. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-31. https://doi.org/10.1016/S0140-6736(03)13638-0
  87. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48. https://doi.org/10.1056/NEJMoa043545
  88. Zhao YY, Weir MA, Manno M, et al. New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med 2012;156:560-9. https://doi.org/10.7326/0003-4819-156-8-201204170-00401
  89. Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med 2014;160:182-9.
  90. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113-32. https://doi.org/10.1016/j.jacc.2010.05.034
  91. Haffner SM, Lehto S, Rönnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-34. https://doi.org/10.1056/NEJM199807233390404
  92. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96. https://doi.org/10.1016/S0140-6736(04)16895-5
  93. Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK; Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high-or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007;147:1-9. https://doi.org/10.7326/0003-4819-147-1-200707030-00002
  94. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011;128 Suppl 5:S213-56. https://doi.org/10.1542/peds.2009-2107C
  95. Gidding SS, Dennison BA, Birch LL, et al. Dietary recommendations for children and adolescents: a guide for practitioners: consensus statement from the American Heart Association. Circulation 2005;112:2061-75. https://doi.org/10.1161/CIRCULATIONAHA.105.169251
  96. McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007;115:1948-67. https://doi.org/10.1161/CIRCULATIONAHA.107.181946
  97. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013;34:3478-90a. https://doi.org/10.1093/eurheartj/eht273
  98. Humphries SE, Whittall RA, Hubbart CS, et al. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J Med Genet 2006;43:943-9. https://doi.org/10.1136/jmg.2006.038356
  99. Defesche JC, Lansberg PJ, Umans-Eckenhausen MA, Kastelein JJ. Advanced method for the identification of patients with inherited hypercholesterolemia. Semin Vasc Med 2004;4:59-65. https://doi.org/10.1055/s-2004-822987
  100. World Health Organization, Human Genetics Programme (CH). WHO/HGN/ H/Cons/99.2. Familial hypercholesterolemia (FH): report of a second WHO consultation. Geneva, 4 September 1998. Geneva: World Health Organization; 1999.
  101. Herrera E, Lasuncion MA, Gomez-Coronado D, Aranda P, Lopez-Luna P, Maier I. Role of lipoprotein lipase activity on lipoprotein metabolism and the fate of circulating triglycerides in pregnancy. Am J Obstet Gynecol 1988;158:1575-83. https://doi.org/10.1016/0002-9378(88)90193-7
  102. Montelongo A, Lasuncion MA, Pallardo LF, Herrera E. Longitudinal study of plasma lipoproteins and hormones during pregnancy in normal and diabetic women. Diabetes 1992;41:1651-9. https://doi.org/10.2337/diab.41.12.1651

Cited by

  1. Impact of low high-density lipoprotein-cholesterol level on 2-year clinical outcomes after acute myocardial infarction in patients with diabetes mellitus vol.15, pp.None, 2016, https://doi.org/10.1186/s12944-016-0374-5
  2. Regular Evaluation for Patients with Diabetes Mellitus vol.17, pp.4, 2016, https://doi.org/10.4093/jkd.2016.17.4.238
  3. Statin and the risk of new-onset diabetes mellitus vol.60, pp.11, 2016, https://doi.org/10.5124/jkma.2017.60.11.901
  4. 이상지질혈증의 국내 및 국외 치료 가이드라인 비교 vol.27, pp.4, 2016, https://doi.org/10.24304/kjcp.2017.27.4.276
  5. Association Between Thyroid Dysfunction and Lipid Profiles Differs According to Age and Sex: Results from the Korean National Health and Nutrition Examination Survey vol.28, pp.7, 2016, https://doi.org/10.1089/thy.2017.0656
  6. The association between alcohol consumption and left ventricular diastolic function and geometry change in general Korean population vol.19, pp.3, 2016, https://doi.org/10.1093/ehjci/jex091
  7. Effects of Statin Intensity on Clinical Outcome in Acute Myocardial Infarction Patients vol.82, pp.4, 2018, https://doi.org/10.1253/circj.cj-17-1221
  8. Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits vol.82, pp.4, 2016, https://doi.org/10.1253/circj.cj-17-1445
  9. Should Measures of High-Density Lipoprotein Function Be Added to the Low-Density Lipoprotein Cholesterol Target Level-Based Guidelines for Prevention of Atherosclerotic Disease? vol.82, pp.5, 2016, https://doi.org/10.1253/circj.cj-18-0358
  10. Statin Intolerance: an Overview of the Current Status and Possible Treatment Options vol.7, pp.2, 2016, https://doi.org/10.12997/jla.2018.7.2.77
  11. Longitudinal association between egg consumption and the risk of cardiovascular disease: interaction with type 2 diabetes mellitus vol.8, pp.None, 2018, https://doi.org/10.1038/s41387-018-0033-1
  12. Epidemiology of Dyslipidemia in the Asia Pacific Region vol.12, pp.1, 2018, https://doi.org/10.1016/j.ijge.2018.02.010
  13. 세월호 참사 후 희생자 부모의 건강상태 변화 vol.14, pp.1, 2016, https://doi.org/10.24986/anxmod.2018.14.1.44
  14. 당귀수산, 생강, 커큐민의 대사성 질환과 관련된 일과성 수용체 전압 이온통로조절에 관한 연구 vol.18, pp.1, 2016, https://doi.org/10.15429/jkomor.2018.18.1.10
  15. Association of hand-grip strength and non-alcoholic fatty liver disease index in older adults vol.22, pp.4, 2016, https://doi.org/10.20463/jenb.2018.0031
  16. Statin-induced liver and muscle toxicities vol.15, pp.1, 2016, https://doi.org/10.1007/s13273-019-0002-3
  17. Maintenance of body weight is an important determinant for the risk of ischemic stroke: A nationwide population-based cohort study vol.14, pp.1, 2016, https://doi.org/10.1371/journal.pone.0210153
  18. The association between low frequency of having breakfast and dyslipidemia in South Korean men and women vol.73, pp.6, 2016, https://doi.org/10.1038/s41430-018-0289-5
  19. 중년남성의 직업에 따른 영양섭취실태와 건강지표의 비교 - 2013년~2016년 국민건강영양조사 자료 이용 - vol.32, pp.3, 2016, https://doi.org/10.9799/ksfan.2019.32.3.216
  20. A Relationship between Dietary Patterns and Dyslipidemia in Urban-dwelling Middle-Aged Korean Men: Using Korean Genome and Epidemiology Study (KoGES) vol.8, pp.3, 2016, https://doi.org/10.7762/cnr.2019.8.3.219
  21. Association between Thyroid-Stimulating Hormone Level after Total Thyroidectomy and Hypercholesterolemia in Female Patients with Differentiated Thyroid Cancer: A Retrospective Study vol.8, pp.8, 2019, https://doi.org/10.3390/jcm8081106
  22. Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study vol.19, pp.1, 2016, https://doi.org/10.1186/s12889-019-7439-0
  23. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up vol.18, pp.None, 2016, https://doi.org/10.1186/s12933-019-0969-z
  24. Dietary pattern, dietary total antioxidant capacity, and dyslipidemia in Korean adults vol.18, pp.1, 2016, https://doi.org/10.1186/s12937-019-0459-x
  25. Association between night work and dyslipidemia in South Korean men and women: a cross-sectional study vol.18, pp.None, 2019, https://doi.org/10.1186/s12944-019-1020-9
  26. Estimated Flavonoid Intake and Analysis of Relevance of Cardiovascular Risk Factors for Pre- and Post-Menopausal Women in Daegu and Gyeongbuk : Based on The Korean National Health and Nutrition Examin vol.29, pp.6, 2016, https://doi.org/10.17495/easdl.2019.12.29.6.538
  27. Physiological Activities of Policosanol Extracted from Sugarcane Wax vol.25, pp.4, 2016, https://doi.org/10.20307/nps.2019.25.4.293
  28. Height Is Associated with Dyslipidemia in Korean Premenopausal Women: Data from the Korea National Health and Nutrition Examination Survey vol.145, pp.11, 2016, https://doi.org/10.1159/000509631
  29. Achievement of the low-density lipoprotein cholesterol goal among patients with dyslipidemia in South Korea vol.15, pp.1, 2020, https://doi.org/10.1371/journal.pone.0228472
  30. Risk factors for cardiovascular disease in ethnic Europeans and Koreans living in the Primorsky Krai vol.19, pp.1, 2016, https://doi.org/10.15829/1728-8800-2020-1-2284
  31. Beneficial effects of Codonopsis lanceolata extract on systolic blood pressure levels in prehypertensive adults: A double‐blind, randomized controlled trial vol.34, pp.2, 2016, https://doi.org/10.1002/ptr.6520
  32. Association between depressive symptoms and arterial stiffness: a cross-sectional study in the general Chinese population vol.10, pp.2, 2016, https://doi.org/10.1136/bmjopen-2019-033408
  33. Association of Dietary Fatty Acid Consumption Patterns with Risk of Hyper-LDL Cholesterolemia in Korean Adults vol.12, pp.5, 2016, https://doi.org/10.3390/nu12051412
  34. The Effect of Smoking on the Association between Long-Term Alcohol Consumption and Dyslipidemia in a Middle-Aged and Older Population vol.55, pp.5, 2020, https://doi.org/10.1093/alcalc/agaa051
  35. Synergistic association of high-sensitivity C-reactive protein and body mass index with insulin resistance in non-diabetic adults vol.10, pp.1, 2016, https://doi.org/10.1038/s41598-020-75390-1
  36. The association between dyslipidemia and the incidence of chronic kidney disease in the general Zhejiang population: a retrospective study vol.21, pp.1, 2016, https://doi.org/10.1186/s12882-020-01907-5
  37. Exposure to ambient fine particulate matter is associated with changes in fasting glucose and lipid profiles: a nationwide cohort study vol.20, pp.1, 2016, https://doi.org/10.1186/s12889-020-08503-0
  38. 한약 복용이 제 2형 당뇨 환자의 혈당 변화에 미치는 영향 : 후항적 차트 리뷰 vol.41, pp.6, 2016, https://doi.org/10.22246/jikm.2020.41.6.1066
  39. Hepatic Steatosis Index in the Detection of Fatty Liver in Patients with Chronic Hepatitis B Receiving Antiviral Therapy vol.15, pp.1, 2016, https://doi.org/10.5009/gnl19301
  40. Dynamics of Serum Retinol and Alpha-Tocopherol Levels According to Non-Alcoholic Fatty Liver Disease Status vol.13, pp.5, 2016, https://doi.org/10.3390/nu13051720
  41. Differing Nutrient Intake and Dietary Patterns According to the Presence of Hyper-Low-Density Lipoprotein Cholesterolemia or Hypertriglyceridemia vol.13, pp.9, 2021, https://doi.org/10.3390/nu13093008
  42. Effects of a Calorie-Restricted Mediterranean-Style Diet on Plasma Lipids in Hypercholesterolemic South Korean Patients vol.13, pp.10, 2016, https://doi.org/10.3390/nu13103393
  43. Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease vol.11, pp.1, 2016, https://doi.org/10.1038/s41598-021-88733-3